Label-free serum proteomics and multivariate data analysis identifies biomarkers and expression trends that differentiate Intraductal papillary mucinous neoplasia from pancreatic adenocarcinoma and healthy controls

Show simple item record

dc.contributor University of Helsinki, HUSLAB en
dc.contributor University of Helsinki, Department of Surgery en
dc.contributor University of Helsinki, HUSLAB en
dc.contributor University of Helsinki, Transplantation Laboratory en
dc.contributor University of Helsinki, CAN-PRO - Translational Cancer Medicine Program en
dc.contributor University of Helsinki, Department of Pathology en
dc.contributor University of Helsinki, HUS Abdominal Center en
dc.contributor University of Helsinki, HUSLAB en
dc.contributor.author Saraswat, Mayank
dc.contributor.author Nieminen, Heini
dc.contributor.author Joenväärä, Sakari
dc.contributor.author Tohmola, Tiialotta
dc.contributor.author Seppänen, Hanna
dc.contributor.author Ristimäki, Ari
dc.contributor.author Haglund, Caj
dc.contributor.author Renkonen, Risto
dc.date.accessioned 2019-12-04T11:00:02Z
dc.date.available 2019-12-04T11:00:02Z
dc.date.issued 2019-05-14
dc.identifier.citation Saraswat , M , Nieminen , H , Joenväärä , S , Tohmola , T , Seppänen , H , Ristimäki , A , Haglund , C & Renkonen , R 2019 , ' Label-free serum proteomics and multivariate data analysis identifies biomarkers and expression trends that differentiate Intraductal papillary mucinous neoplasia from pancreatic adenocarcinoma and healthy controls ' , Translational Medicine Communications , vol. 4 , 6 . https://doi.org/10.1186/s41231-019-0037-4 en
dc.identifier.issn 2396-832X
dc.identifier.other PURE: 126403148
dc.identifier.other PURE UUID: 3171419f-2e2e-40fa-9910-a2f4e33adf12
dc.identifier.uri http://hdl.handle.net/10138/307884
dc.description.abstract Background Intraductal Papillary Mucinous Neoplasia (IPMN) are potentially malignant cystic tumors of the pancreas. IPMN can progress from low to moderate to high grade dysplasia and further to IPMN associated carcinoma. Often the difference between benign and malignant nature of the IPMN is not clear preoperatively. We aim to elucidate molecular expression patterns of various grades of IPMN and pancreatic carcinoma. Additionally we suggest potential novel biomarkers to differentiate IPMN from healthy individuals and pancreatic carcinoma to enable early detection as well as help in differential diagnosis in future. Methods We have performed retrospective label-free proteomic analysis of the serum samples from 44 patients with various grades of benign IPMN or IPMN associated carcinoma and 11 healthy controls. Proteomic data was further analyzed by various multivariate statistical methods. Four groups of samples (low-grade, high-grade IPMN, pancreatic carcinoma and age- and sex-matched healthy controls) were compared with ANOVA. Orthogonal projections to latent structures-discriminant analysis (OPLS-DA) modeling gave S-plot for feature selection. Stringently selected potential markers were further evaluated with ROC curve analysis and area under the curve was calculated. Differentially expressed proteins were used for pathway analysis. Linear trend analysis (Mann Kendall test) was used for identifying significant increasing or decreasing trends from healthy-low grade-high grade IPMN-pancreatic carcinoma. Results Based on protein expression (436 proteins quantified), PCA separated most sample groups from each other. S-Plot selected biomarker panels with moderate to very high AUC values for differentiating controls from Low-, High-Grade IPMN and carcinoma. Linear trend analysis identified 12 proteins which were consistently increasing or decreasing trend among the groups. We found potential biomarkers to differentiate healthy controls from different degrees of dysplasia and pancreatic carcinoma. These biomarkers can classify IPMN, carcinoma and healthy controls from each other which is an unmet clinical need. Data are available via ProteomeXchange with identifier PXD009139. Conclusion Kininogen-1 was able to differentiate healthy persons from low and high-grade IPMN. Retinol binding protein-4 could classify the low-grade IPMN from pancreatic carcinoma. Twelve proteins including apolipoproteins and complement proteins had significantly increasing or decreasing trends from healthy to low to high-grade IPMN to pancreatic carcinoma. fi
dc.format.extent 12
dc.language.iso eng
dc.relation.ispartof Translational Medicine Communications
dc.relation.uri http://hdl.handle.net/10138/301862
dc.rights en
dc.subject 3111 Biomedicine en
dc.title Label-free serum proteomics and multivariate data analysis identifies biomarkers and expression trends that differentiate Intraductal papillary mucinous neoplasia from pancreatic adenocarcinoma and healthy controls en
dc.type Article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.1186/s41231-019-0037-4
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/publishedVersion
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
document_2.pdf 1.548Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record